Progress in studies of MicroRNA-144-associated diseases and related mechanism

doi:10.3969/j.issn.1006-7795.2013.01.015

Abstract

Abstract:

MicroRNAs (miRs) play a prominent role in a variety of physiological, pathological and biological processes, including the individual development, cell proliferation, differentiation, apoptosis, and oncogenesis by binding to target transcripts for cleavage or translational repression. Recently, a new class of miRs called ‘circulating miRs’ was found in cell-free body fluids such as plasma and urine. Circulating miRs have been shown to be very stable, specific, and sensitive biomarkers. Among the identified miRs thus far, ~50% of mammalian miRs are clustered in the genome and transcribed as polycistronic primary transcripts. Recent studies have demonstrated that miR-144 is the important regulator of erythroid differentiation, and is involved in the tumor development and cardio-cerebrovascular disease. The pre-miR-144 exists as bicistronic locus miR-144/451, and this article reviews the effect and possible regulating mechanisms of miR-144 in the blood disease, disorder of the nervous system, cancer, heart disease based on recently published literature.

Key words: microRNA-144, erythropoiesis, leukemia, cancer, myocardial ischemia

CLC Number:

R743

ZHAO Haiping, LUO Yumin. Progress in studies of MicroRNA-144-associated diseases and related mechanism[J]. Journal of Capital Medical University, 2013, 34(1): 80-85.

0
/ / Recommend

Add to citation manager EndNote|Reference Manager|ProCite|BibTeX|RefWorks

URL: https://journal03.magtech.org.cn/Jweb_sdykdxxb/EN/10.3969/j.issn.1006-7795.2013.01.015

https://journal03.magtech.org.cn/Jweb_sdykdxxb/EN/Y2013/V34/I1/80

References

[1] Ghelani H S, Rachchh M A, Gokani R H. MicroRNAs as newer therapeutic targets: A big hope from a tiny player[J]. J Pharmacol Pharmacother, 2012, 3(3): 217-227.

[2] Zen K, Zhang C Y. Circulating microRNAs: a novel class of biomarkers to diagnose and monitor human cancers[J]. Med Res Rev, 2012, 32(2):326-348.

[3] Rüegger S, Groβhans H. MicroRNA turnover: when, how, and why. Trends Biochem Sci[J]. Trends Biochem Sci, 2012, 37(10):436-446.

[4] Bianchi N, Zuccato C, Finotti A, et al. Involvement of miRNA in erythroid differentiation[J]. Epigenomics, 2012, 4(1):51-65.

[5] Lin He, Hannon G J. MicroRNAs: small RNAs with a big role in gene regulation[J]. Nature Reviews Genetics, 2004, 5(7): 522-531.

[6] Dore L C, Amigo J D, Dos Santos C O, et al. A GATA-1-regulated microRNA locus essential for erythropoiesis[J]. Proc Natl Acad Sci USA, 2008, 105(9):3333-3338.

[7] Papapetrou E P, Korkola J E, Sadelain M. A genetic strategy for single and combinatorial analysis of miRNA function in mammalian hematopoietic stem cells[J]. Stem Cells, 2010, 28(2):287-296.

[8] Du T T, Fu Y F, Dong M, et al. Experimental validation and complexity of miRNA-mRNA target interaction during zebrafish primitive erythropoiesis[J]. Biochem Biophys Res Commun, 2009, 381(4):688-693.

[9] Fu Y F, Du T T, Dong M, et al. Mir-144 selectively regulates embryonic alpha-hemoglobin synthesis during primitive erythropoiesis[J]. Blood, 2009, 113(6):1340-1349.

[10] Rasmussen K D, Simmini S, Abreu-Goodger C, et al. The miR-144/451 locus is required for erythroid homeostasis[J]. J Exp Med, 2010, 207(7):1351-1358.

[11] Yu D, dos Santos C O, Zhao G, et al. miR-451 protects against erythroid oxidant stress by repressing 14-3-3zeta[J]. Genes Dev, 2010, 24(15):1620-1633.

[12] Sangokoya C, Telen M J, Chi J T. microRNA miR-144 modulates oxidative stress tolerance and associates with anemia severity in sickle cell disease[J]. Blood, 2010, 116(20):4338-4348.

[13] Rasmussen K D, O'Carroll D. The miR-144/451eGFP allele, a novel tool for resolving the erythroid potential of hematopoietic precursors[J]. Blood, 2011, 118(11):2988-2992.

[14] Leuenberger N, Jan N, Pradervand S, et al. Circulating microRNAs as long-term biomarkers for the detection of erythropoiesis-stimulating agent abuse[J]. Drug Test Anal, 2011, 3(11-12):771-776.

[15] Liu L, Wang S, Chen R, et al. Myc induced miR-144/451 contributes to the acquired imatinib resistance in chronic myelogenous leukemia cell K562[J]. Biochem Biophys Res Commun, 2012, 425(2):368-373.

[16] Girardi C, De Pittà C, Casara S, et al. Analysis of miRNA and mRNA expression profiles highlights alterations in ionizing radiation response of human lymphocytes under modeled microgravity[J]. PLoS One, 2012, 7(2):e31293.

[17] Machová Poláková K, Lopotová T, Klamová H, et al. Expression patterns of microRNAs associated with CML phases and their disease related targets[J]. Mol Cancer, 2011, 10:41.

[18] Whitman S P, Maharry K, Radmacher M D, et al. FLT3 internal tandem duplication associates with adverse outcome and gene- and microRNA-expression signatures in patients 60 years of age or older with primary cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study[J]. Blood, 2010, 116(18):3622-3626.

[19] 赵晓鸿,赫捷.微小RNA与肿瘤[J].中华肿瘤防治杂志,2010,17(7):547-550.

[20] Wang W, Peng B, Wang D, et al. Human tumor microRNA signatures derived from large-scale oligonucleotide microarray datasets[J]. Int J Cancer,2011, 129(7):1624-1634.

[21] Wang P, Fu T, Wang X, et al. Primary, study of miRNA expression patterns in laryngeal carcinoma by microarra[J]. Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi, 2010, 24(12):535-538.

[22] Guled M, Lahti L, Lindholm P M, et al. CDKN2A, NF2, and JUN are dysregulated among other genes by miRNAs in malignant mesothelioma -A miRNA microarray analysis[J]. Genes Chromosomes Cancer, 2009, 48(7):615-623.

[23] Rossing M, Borup R, Henao R, et al. Down-regulation of microRNAs controlling tumourigenic factors in follicular thyroid carcinoma[J]. J Mol Endocrinol, 2012, 48(1):11-23.

[24] 魏任雄, 蔡林, 谭金海, 等. 骨肉瘤miRNA基因的差异性表达[J]. 中华实验外科杂志, 2009, 26(5): 636-638.

[25] Gaedcke J, Grade M, Camps J, et al. The rectal cancer microRNAome-microRNA expression in rectal cancer and matched normal mucosa[J]. Clin Cancer Res, 2012, 18(18):4919-4930.

[26] Kalimutho M, Del Vecchio Blanco G, Di Cecilia S, et al. Differential expression of miR-144* as a novel fecal-based diagnostic marker for colorectal cancer[J]. J Gastroenterol, 2011, 46(12):1391-1402.

[27] Sureban S M, May R, Mondalek F G, et al. Nanoparticle-based delivery of siDCAMKL-1 increases microRNA-144 and inhibits colorectal cancer tumor growth via a Notch-1 dependent mechanism[J]. J Nanobiotechnology, 2011, 9:40.

[28] Lee D Y, Jeyapalan Z, Fang L, et al. Expression of versican 3'-untranslated region modulates endogenous microRNA functions[J]. PLoS One, 2010, 5(10):e13599.

[29] 曹婷,杨丽君,崔红.微小RNA在神经系统及髓鞘发生的调节作用[J].首都医科大学学报,2012,33(3):414-418.

[30] Zhang H Y, Zheng S J, Zhao J H, et al. MicroRNAs 144, 145, and 214 are down-regulated in primary neurons responding to sciatic nerve transection[J]. Brain Res, 2011, 1383:62-70.

[31] Rau C S, Jeng J C, Jeng S F, et al. Entrapment neuropathy results in different microRNA expression patterns from denervation injury in rats[J]. BMC Musculoskelet Disord, 2010, 11:181.

[32] An J, Choi K P, Wells C A, et al. Identifying co-regulating microRNA groups[J]. J Bioinform Comput Biol, 2010, 8(1):99-115.

[33] Persengiev S, Kondova I, Otting N, et al. Genome-wide analysis of miRNA expression reveals a potential role for miR-144 in brain aging and spinocerebellar ataxia pathogenesis[J]. Neurobiol Aging, 2011, 32(12):2316.e17-27.

[34] Gu H, Li H, Zhang L, et al. Diagnostic role of microRNA expression profile in the serum of pregnant women with fetuses with neural tube defects[J]. J Neurochem, 2012, 122(3):641-649.

[35] Zhou R, Yuan P, Wang Y, et al. Evidence for selective microRNAs and their effectors as common long-term targets for the actions of mood stabilizers[J]. Neuropsychopharmacology, 2009, 34(6):1395-1405.

[36] Dinan T G. MicroRNAs as a target for novel antipsychotics: a systematic review of an emerging field[J]. Int J Neuropsychopharmacol, 2010, 13(3):395-404.

[37] 施翔翔, 来丹丹, 章佳颖, 等. 心脏发育相关的微小RNA差异表达[J]. 中华医学杂志, 2009, 89(20):90-96.

[38] Wang X, Zhu H, Zhang X, et al. Loss of the miR-144/451 cluster impairs ischaemic preconditioning-mediated cardioprotection by targeting Rac-1[J]. Cardiovasc Res, 2012, 94(2):379-390.

[39] Zhang X, Wang X, Zhu H, et al. Synergistic effects of the GATA-4-mediated miR-144/451 cluster in protection against simulated ischemia/reperfusion-induced cardiomyocyte death[J]. J Mol Cell Cardiol, 2010, 49(5):841-850.

[40] Ovcharenko D, Kelnar K, Johnson C, et al. Genome-scale microRNA and small interfering RNA screens identify small RNA modulators of TRAIL-induced apoptosis pathway[J]. Cancer Res, 2007, 67(22):10782-10788.

[41] Huang F, Huang XY, Yan DS, et al. MicroRNA-144 over-expression induced myocytes apoptosis[J]. Zhonghua Xin Xue Guan Bing Za Zhi, 2011, 39(4):353-357.

[42] Wu J H, Gao Y, Ren A J, et al. Altered microRNA expression profiles in retinas with diabetic retinopathy[J]. Ophthalmic Res, 2012, 47(4):195-201.

[43] Karolina D S, Armugam A, Tavintharan S, et al. MicroRNA 144 impairs insulin signaling by inhibiting the expression of insulin receptor substrate 1 in type 2 diabetes mellitus[J]. PLoS One, 2011, 6(8):e22839.

[44] Xie T, Liang J, Guo R, et al. Comprehensive microRNA analysis in bleomycin-induced pulmonary fibrosis identifies multiple sites of molecular regulation[J]. Physiol Genomics, 2011, 43(9):479-487.

[45] Liu Y, Wang X, Jiang J, et al. Modulation of T cell cytokine production by miR-144* with elevated expression in patients with pulmonary tuberculosis[J]. Mol Immunol, 2011, 48(9-10):1084-1090.

[46] Chaveles I, Zaravinos A, Habeos I G, et al. MicroRNA profiling in murine liver after partial hepatectomy[J]. Int J Mol Med, 2012, 29(5):747-755.

[47] Katsuura S, Kuwano Y, Yamagishi N, et al. MicroRNAs miR-144/144* and miR-16 in peripheral blood are potential biomarkers for naturalistic stress in healthy Japanese medical students[J]. Neurosci Lett, 2012, 516(1):79-84.